GLP-1 receptor agonists demonstrate striking efficacy in prediabetes reversal, with tirzepatide achieving normoglycemia in 93.3% of patients, semaglutide in 81%, and liraglutide in 66%. These medications also significantly delayed progression to type 2 diabetes while reducing HbA1c, fasting glucose, and body weight. The interventions represents a potential paradigm shift in prediabetes management, moving beyond lifestyle modifications to pharmacological prevention. Currently, prediabetes affects over 96 million Americans, with 5-10% progressing to diabetes annually without intervention. The ability to reverse metabolic dysfunction at this critical inflection point could dramatically reduce the diabetes epidemic's trajectory. Beyond glucose control, these agents showed cardiovascular benefits and improvements in liver function, suggesting systemic metabolic restoration. However, the sustainability challenge looms large—benefits partially diminished after drug withdrawal, indicating potential need for long-term treatment. The gastrointestinal side effects remain manageable, but cost and accessibility barriers may limit widespread implementation. This evidence positions GLP-1 agonists as potentially transformative tools for diabetes prevention, though larger randomized trials are needed to establish definitive treatment protocols and identify optimal candidates for intervention.